The probability of headache relief after first administration was 68.6% for rizatriptan, 62.7% for sumatriptan and 37.9% for Cafergot.

The probability of headache recurrence was 36.9% for rizatriptan, 27.8% for sumatriptan and 15.3% for Cafergot.

The probability of enduring a headache if headache was not relieved by first administration was 90%.

The probability of dizziness was 6.7% for rizatriptan, 5.8% for sumatriptan and 5.3% for Cafergot.

The probability of nausea was 4.2% for rizatriptan, 6.9% for sumatriptan and 8.5% for Cafergot.

The probability of somnolence was 5.5% for rizatriptan, 6.7% for sumatriptan and 2.3% for Cafergot.

The probability of chest pain was 0.7% for rizatriptan, 2.4% for sumatriptan and 0.8% for Cafergot.

The probability of headache relief in the ER was 94%.

The probability of switching to Cafergot from rizatriptan was 30.1%.

The probability of switching to rizatriptan from Cafergot was 69.9%.

The probability of switching to sumatriptan from rizatriptan was 35.7%.

The probability of switching to rizatriptan from sumatriptan was 64.3%.